大部分患者为低分级非肌层浸润性膀胱癌 (non-muscle-invasive bladder cancer, NMIBC)。此类患者的肿瘤复发风险高,但疾病进展和死亡风险低。高分级 NMIBC,尤其当侵入黏膜固有层或与原位癌 (CIS) 相关时,其复发和进展风险均较高。而且如果膀胱灌注治疗失败,则应接受膀胱切除术治疗。一旦发生肌层浸润,即使接受膀胱切除术治疗,总生存率为 50%。以顺铂为基础的联合化疗可经常产生客观反应,但仅有<10%的转移性疾病患者得以治愈。[96]Lamm DL, Riggs DR, Traynelis CT, et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder. J Urol. 1995;153:1444-50.http://www.ncbi.nlm.nih.gov/pubmed/7714962?tool=bestpractice.com
低风险膀胱癌
低分级、单发、非浸润性膀胱癌 15 年内的复发风险为 65%,但仅 <5% 的患者有进展。膀胱灌注化疗可降低 2 年复发风险高达 20%。[97]Lamm D, Colombel M, Persad R, et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol. 2008;7:651-666. 对于中等风险或高风险的膀胱癌患者,膀胱灌注化疗的疗效不具有重复性。[98]Gudjonsson S, Adell L, Merdasa F, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009;55:773-780.http://www.ncbi.nlm.nih.gov/pubmed/19153001?tool=bestpractice.com
中等风险膀胱癌
体积较大、多灶性或复发性低分级 Ta 期膀胱癌可增加疾病复发和进展的风险。若不治疗,15 年复发风险接近 90%。膀胱灌注化疗短期可降低复发率达 20%,但对长期复发的作用较小,且未发现其可减缓进展。在一项大型随机、对照临床试验 (RCT) 中,为期 3 周的卡介苗 (BCG) 免疫维持治疗,虽然其毒性大于化疗,但显著降低了膀胱癌的复发、转移以及死亡。[53]Lamm DL, Torti F. Bladder cancer, 1996. CA Cancer J Clin. 1996;46:93-112.http://onlinelibrary.wiley.com/doi/10.3322/canjclin.46.2.93/fullhttp://www.ncbi.nlm.nih.gov/pubmed/8624800?tool=bestpractice.com[99]Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56:247-256.http://www.ncbi.nlm.nih.gov/pubmed/19409692?tool=bestpractice.com
[Figure caption and citation for the preceding image starts]: 低分级非浸润性 (Ta) 乳头状尿路上皮癌;注意邻近卫星灶,表明存在场效应 (field effect)(图片)由 Donald Lamm, MD, FACS 提供 [Citation ends].
[Figure caption and citation for the preceding image starts]: 低分级尿路上皮癌种植在尿道前列腺部;图中显示用于切除膀胱肿瘤的环状电极(图片)由 Donald Lamm, MD, FACS 提供 [Citation ends].
[Figure caption and citation for the preceding image starts]: 低分级肿瘤由小卫星灶(小而均匀的叶状体)包围。处于最突出位置的是广基实体瘤,这是高分级肿瘤的典型外观。低分级和高分级肿瘤经常存在于同一例患者中(图片)由 Donald Lamm, MD, FACS 提供 [Citation ends].
高风险膀胱癌
CIS、高分级、T1 期浸润性膀胱癌是最危险的 NMIBC 种类,其疾病进展和死亡的风险较高。此类患者治疗失败的风险约为 50%,疾病进展风险为 15%。[42]Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997;158:62-67. 复发风险高和/或病情有进展的患者对于目前建议的 1 至 3 年维持治疗 BCG 计划表现不佳,且迫切需要进行替代治疗。[100]Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guérin. Eur Urol. 2016;69:60-9.http://www.ncbi.nlm.nih.gov/pubmed/26210894?tool=bestpractice.com 如果存在多个危险因素,例如复发、多发性高分级 T1 期肿瘤、原发性高分级 T1 期肿瘤伴弥漫性原位癌 (CIS) 或淋巴血管浸润,适用膀胱切除术。然而,对于大多数高风险患者,膀胱切除术属于过度治疗。